Literature DB >> 15541837

Mortality following non-ST elevation acute coronary syndrome: 4 years follow-up of the PRAIS UK Registry (Prospective Registry of Acute Ischaemic Syndromes in the UK).

Anil K Taneja1, Julian Collinson, Marcus D Flather, Ameet Bakhai, Diego Perez de Arenaza, Duolao Wang, Jennifer Adgey, Keith A A Fox.   

Abstract

AIM: To present information on long-term prognosis and risk factors following an admission with non-ST elevation acute coronary syndrome.
METHODS: A cohort of 653 patients was followed for mortality and causes of death using data from the UK Office of National Statistics (ONS). Cox proportional hazards model was used to identify the prognostic factors.
RESULTS: Overall survival at a maximum follow-up of 45 months was 77.8% (95% CI 74.1-81.1%). Seventy-three per cent of the deaths were clearly due to a cardiovascular cause. Age, male gender, heart failure, ST depression or bundle branch block were all associated with higher short- and long-term risk. Taking aspirin or having a revascularization procedure, over the period of six months following initial hospitalisation were both associated with a lower long-term risk.
CONCLUSION: Non-ST elevation acute coronary syndromes carry a high risk of death over a 4-year period. Conventional risk factors can predict both short- and long-term risk. More invasive management and the use of evidence-based therapies appear to be associated with a lower risk.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15541837     DOI: 10.1016/j.ehj.2004.08.009

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  6 in total

Review 1.  Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.

Authors:  Katherine A Lyseng-Williamson; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Effects of comorbidity and hospital care on 6-month mortality in patients with elevated cardiac troponin T.

Authors:  P Wong; A Ramsewak; S Murray; A Robinson; D Robinson; E Rodrigues
Journal:  Postgrad Med J       Date:  2007-05       Impact factor: 2.401

3.  Long term clinical outcome and bleeding complications among hospital survivors with acute coronary syndromes.

Authors:  P Wong; A Robinson; S Shaw; E Rodrigues
Journal:  Postgrad Med J       Date:  2006-03       Impact factor: 2.401

Review 4.  Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective.

Authors:  Bart Heeg; Joep Damen; Ben Van Hout
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

5.  Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand.

Authors:  Sukit Yamwong; Unchalee Permsuwan; Sirana Tinmanee; Piyamitr Sritara
Journal:  Health Econ Rev       Date:  2014-11-14

6.  Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5).

Authors:  Jorge Alfonso Ross Terres; G Lozano-Ortega; R Kendall; M J Sculpher
Journal:  BMC Cardiovasc Disord       Date:  2015-12-29       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.